查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1925117

全球生物製药合约服务市场预测至2032年：按服务类型、研究服务、技术、应用、最终用户和地区划分

Biopharma Contract Services Market Forecasts to 2032 - Global Analysis By Service Type, Research Service, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的一项研究，预计到 2025 年，全球生物製药合约服务市场规模将达到 270.1 亿美元，到 2032 年将达到 519.7 亿美元，预测期内复合年增长率为 9.8%。

生物製药合约服务是指为生物技术和製药公司提供的专业外包解决方案，旨在支援治疗产品的研发和商业化。这些服务涵盖广泛的领域，包括合约研究组织 (CRO)、契约製造(CMO)、临床试验管理、法规遵循、分析测试和品质保证。透过利用外部专业知识和基础设施，生物製药公司可以加快药物研发进程、降低营运成本并减少风险，同时确保符合严格的监管标准。这些伙伴关係能够提供扩充性、柔软性且创新的解决方案，从而提高全球生物製药生态系统中临床前研究、临床试验、生产和上市后支援等各阶段的效率和准确性。

生物製药和生物相似药的需求不断增长

生物製剂和生物相似药需求的不断增长是生物製药合约服务市场的主要驱动力。慢性病和复杂疾病的日益普遍，以及标靶治疗的兴起，推动了外包研发和生产解决方案的需求。合约服务使生物製药公司能够加速生物製药和生物相似药的生产，优化临床试验效率，并确保符合监管要求。这种不断增长的需求透过促进先进基础设施、专业知识和可扩展的创新疗法解决方案的获取，推动了市场扩张。

高昂的资本和营运成本

高昂的资本投入和营运成本仍是限制市场发展的主要因素。建立先进的设施、维持合规营运以及实施先进技术都需要大量资金。由于预算限制，小规模的生技公司可能难以获得全面的合约服务。此外，持续的专业人员配备、设备维护和品质保证也增加了营运负担。这些财务和后勤压力可能会延缓专案实施，并限制市场成长。

技术进步

技术进步为市场带来了巨大的成长机会。自动化、高通量筛检、分子诊断和先进分析技术的创新，使得药物研发更快速精准。透过采用这些技术，合约服务供应商可以提高效率、减少错误，并为复杂的生物製药、生物相似药和个人化药物提供可扩展的解决方案。运用尖端工具的公司能够获得竞争优势，拓展服务范围，从而为临床前、临床和商业化阶段的持续成长奠定市场基础。

供应链脆弱性

供应链脆弱性对市场构成重大威胁。由于依赖全球供应商提供原料、专用设备和先进试剂，市场极易受到地缘政治紧张局势、监管变化和物流挑战的影响。生产中断和临床试验用品的延迟供应会影响进度、增加成本并损害品质标准。为了因应这些脆弱性，在高度监管且时间紧迫的产业中，强有力的风险管理、策略采购和紧急时应对计画对于维持服务连续性和保障市场成长至关重要。

新冠疫情的影响：

新冠疫情对市场产生了重大影响。它扰乱了供应链、临床试验和生产运营，同时加速了外包的普及，因为企业正在寻求灵活且扩充性的解决方案以维持研发效率。合约服务供应商在支持疫苗研发、快速检测和治疗方法创新方面发挥了关键作用。疫情驱动的数位转型、远端监控、分散式检测和先进分析技术的应用进一步巩固了市场地位。

预计在预测期内，临床试验领域将占据最大的市场份额。

由于药物研发计画（尤其是生物製药和生物相似药）的复杂性和规模日益扩大，预计在预测期内，临床试验领域将占据最大的市场份额。外包临床试验管理使生物製药公司能够获得专业知识、提高患者招募率、确保符合监管要求并提升营运效率。因此，临床试验服务对于加快产品上市速度，同时维持高标准的资料品质和安全性至关重要。

在预测期内，製药公司板块将呈现最高的复合年增长率。

由于外包模式的日益普及，製药公司预计将在预测期内实现最高成长率，这主要得益于其在优化研发效率、降低成本和规避复杂药物开发风险方面所采取的策略。与生物製药合约服务供应商合作，使製药公司能够利用先进的分析技术、法规支援和可扩展的生产能力。此外，对创新疗法、生物相似药和个人化医疗日益增长的需求，也进一步巩固了製药公司在全球市场扩张中的关键驱动力地位。

占比最大的地区：

由于生物製药行业的成长、临床研究基础设施的不断完善、高性价比的外包解决方案以及政府的支持性政策，亚太地区预计将在预测期内占据最大的市场份额。生物製药和生物相似药产量的不断增长，加上该地区熟练的劳动力和有利的监管改革，使其成为生物製药合约服务的战略要地。全球企业与当地企业之间的强大合作关係进一步巩固了该地区的市场主导地位。

年复合成长率最高的地区：

在预测期内，由于生物製药外包领域的技术创新，北美预计将实现最高的复合年增长率。该地区受益于许多大型製药和生物技术公司的高度集中，这些公司寻求专业的合约服务，以加速临床试验、确保法规遵循并实现生产製造。对个人化医疗、生物相似药和生物製药日益增长的需求，加上健全的法规结构，使北美成为扩充性、高品质生物製药合约解决方案快速成长的市场。

免费客製化服务资讯：

购买此报告的客户可以选择以下免费自订选项之一：

  • 公司概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要企业SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户要求，对主要国家进行市场估算和预测，并计算复合年增长率（註：可行性需确认）。
  • 竞争标竿分析
    • 根据主要参与者的产品系列、地理覆盖范围和策略联盟进行基准分析

目录

第一章执行摘要

第二章 前言

  • 概括
  • 相关利益者
  • 调查范围
  • 调查方法
  • 研究材料

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球生物製药合约服务市场（依服务类型划分）

  • 委外研发机构(CRO) 服务
    • 临床前服务
    • 监管事务服务
    • 临床试验服务
  • 受託製造厂商(CMO) 服务
    • 生物製药生产
    • 细胞及基因治疗製造
    • 小分子药物生产
  • 合约开发与受託製造厂商(CDMO) 服务
    • 药物开发服务
    • 分析和品质测试
    • 配方开发

6. 全球生物製药合约服务市场（依研究服务划分）

  • 肿瘤学
  • 发炎/免疫学
  • 疫苗
  • 心臟病学
  • 其他的

7. 全球生物製药合约服务市场（依技术划分）

  • 生物製药
  • 基因治疗
  • 低分子
  • 细胞疗法

8. 全球生物製药合约服务市场（按应用领域划分）

  • 临床试验
  • 药物研发
  • 药物发现
  • 其他的

9. 全球生物製药合约服务市场（依最终用户划分）

  • 製药公司
  • 生技公司
  • 研究机构和学术中心

第十章：全球生物製药合约服务市场（按地区划分）

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 併购
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章 企业概况

  • Thermo Fisher Scientific Inc.
  • KBI Biopharma
  • Lonza Group AG
  • Cambrex Corporation
  • WuXi AppTec
  • Charles River Laboratories
  • WuXi Biologics
  • AbbVie Contract Manufacturing
  • Catalent Inc.
  • FUJIFILM Diosynth Biotechnologies
  • Samsung Biologics
  • Boehringer Ingelheim BioXcellence
  • Recipharm AB
  • Rentschler Biopharma SE
  • AGC Biologics
Product Code: SMRC33511

According to Stratistics MRC, the Global Biopharma Contract Services Market is accounted for $27.01 billion in 2025 and is expected to reach $51.97 billion by 2032 growing at a CAGR of 9.8% during the forecast period. Biopharma Contract Services refer to specialized outsourcing solutions provided to biotechnology and pharmaceutical companies to support the research, development, and commercialization of therapeutic products. These services encompass a wide spectrum, including contract research (CRO), contract manufacturing (CMO), clinical trial management, regulatory compliance, analytical testing, and quality assurance. By leveraging external expertise and infrastructure, biopharma companies can accelerate drug development timelines, reduce operational costs, and mitigate risk while maintaining compliance with stringent regulatory standards. These partnerships enable scalable, flexible, and innovative solutions, fostering efficiency and precision across preclinical research, clinical trials, manufacturing, and post-market support within the global biopharmaceutical ecosystem.

Market Dynamics:

Driver:

Rising Demand for Biologics & Biosimilars

The growing demand for biologics and biosimilars is a primary driver of the Biopharma Contract Services Market. Increasing prevalence of chronic and complex diseases, coupled with a shift toward targeted therapies, has intensified the need for outsourced development and manufacturing solutions. Contract services enable biopharma companies to accelerate biologics and biosimilar production, optimize clinical trial efficiency, and ensure regulatory compliance. This rising demand supports market expansion by facilitating access to advanced infrastructure, specialized expertise, and scalable solutions for innovative therapeutics.

Restraint:

High Capital & Operational Costs

High capital investment and operational costs remain significant restraints for the Market. Establishing advanced facilities, maintaining regulatory compliance, and implementing sophisticated technologies require substantial financial resources. Smaller biotechnology firms may face challenges accessing comprehensive contract services due to budget constraints. Additionally, the continuous need for skilled personnel, equipment maintenance, and quality assurance increases operational burdens. These financial and logistical pressures can slow adoption and limit market growth.

Opportunity:

Advancements in technology

Technological advancements present significant growth opportunities in the market. Innovations in automation, high-throughput screening, molecular diagnostics, and advanced analytics enable faster, more accurate drug development. By adopting these technologies, contract service providers can enhance efficiency, reduce errors, and offer scalable solutions for complex biologics, biosimilars, and personalized medicines. Companies that leverage cutting-edge tools gain competitive advantage and expand service offerings, positioning the market for sustained growth across preclinical, clinical, and commercial phases.

Threat:

Supply Chain Vulnerabilities

Supply chain vulnerabilities pose a notable threat to the market. Dependence on global suppliers for raw materials, specialized equipment, and advanced reagents exposes the sector to disruptions from geopolitical tensions, regulatory changes, or logistical challenges. Interruptions in production and delays in clinical trial materials can impact timelines, increase costs, and compromise quality standards. Such vulnerabilities necessitate robust risk management, strategic sourcing, and contingency planning to maintain service continuity and protect market growth in a highly regulated, time-sensitive industry.

Covid-19 Impact:

The COVID-19 pandemic significantly influenced the market. While it disrupted supply chains, clinical trials, and manufacturing operations, it also accelerated outsourcing adoption as companies sought flexible, scalable solutions to maintain R&D productivity. Contract service providers played a key role in supporting vaccine development, rapid testing, and therapeutic innovations. Pandemic-driven digital transformation and adoption of remote monitoring, decentralized trials, and advanced analytics further strengthened the market.

The clinical trials segment is expected to be the largest during the forecast period

The clinical trials segment is expected to account for the largest market share during the forecast period, due to increasing complexity and volume of drug development programs, particularly for biologics and biosimilars. Outsourcing clinical trial management enables biopharma companies to access specialized expertise, enhance patient recruitment, ensure regulatory compliance, and streamline operational efficiency. As a result, clinical trial services remain critical for accelerating time-to-market while maintaining high standards of data quality and safety.

The pharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pharmaceutical companies segment is predicted to witness the highest growth rate, due to rising outsourcing adoption to optimize R&D productivity, reduce costs, and mitigate risks associated with complex drug development. By partnering with biopharma contract service providers, pharmaceutical firms can leverage advanced analytical technologies, regulatory support, and scalable manufacturing capabilities. Increasing demand for innovative therapeutics, biosimilars, and personalized medicine further positions pharmaceutical companies as key drivers of market expansion globally.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to growing biopharmaceutical industry, expanding clinical research infrastructure, cost-effective outsourcing solutions, and supportive government initiatives. Increasing biologics and biosimilar production, coupled with the region's skilled workforce and favorable regulatory reforms, enhances its appeal as a strategic hub for biopharma contract services. Strong partnerships between global and local players further reinforce regional market dominance.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to technological innovation in biopharma outsourcing. The region benefits from a high concentration of leading pharmaceutical and biotechnology companies seeking specialized contract services to accelerate clinical trials, regulatory compliance, and manufacturing. Increasing demand for personalized medicine, biosimilars, and biologics, alongside strong regulatory frameworks, positions North America as a rapidly growing market for scalable, high-quality biopharma contract solutions.

Key players in the market

Some of the key players in Biopharma Contract Services Market include Thermo Fisher Scientific Inc., KBI Biopharma, Lonza Group AG, Cambrex Corporation, WuXi AppTec, Charles River Laboratories, WuXi Biologics, AbbVie Contract Manufacturing, Catalent Inc., FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Boehringer Ingelheim BioXcellence, Recipharm AB, Rentschler Biopharma SE and AGC Biologics.

Key Developments:

In January 2026, TetraScience has entered a strategic collaboration with Thermo Fisher Scientific to accelerate scientific data transformation and AI enablement across biopharma laboratories. By integrating Thermo Fisher's instruments and informatics with TetraScience's AI-native data platform and intelligent workflows, the partnership aims to standardize fragmented lab data and power scalable, high-value AI use cases that enhance reproducibility, throughput, and decision-making in R&D and manufacturing.

In October 2025, Thermo Fisher Scientific's PPD clinical research arm has forged a new R&D partnership with AstraZeneca's BioVentureHub in Gothenburg, Sweden, co-locating teams to collaborate on projects in chromatography, molecular genomics and proteomics, boosting innovation and strengthening the life science ecosystem.

Service Types Covered:

  • Contract Research Organization (CRO) Services
  • Contract Manufacturing Organization (CMO) Services
  • Contract Development and Manufacturing Organization (CDMO) Services

Research Services Covered:

  • Oncology
  • Inflammation & Immunology
  • Vaccines
  • Cardiology
  • Other Research Services

Technologies Covered:

  • Biologics
  • Gene Therapy
  • Small Molecules
  • Cell Therapy

Applications Covered:

  • Clinical Trials
  • Drug Development
  • Drug Discovery
  • Other Applications

End Users Covered:

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Research Institutes & Academic Centers

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biopharma Contract Services Market, By Service Type

  • 5.1 Introduction
  • 5.2 Contract Research Organization (CRO) Services
    • 5.2.1 Preclinical Services
    • 5.2.2 Regulatory Affairs Services
    • 5.2.3 Clinical Trial Services
  • 5.3 Contract Manufacturing Organization (CMO) Services
    • 5.3.1 Biologic Manufacturing
    • 5.3.2 Cell and Gene Therapy Manufacturing
    • 5.3.3 Small Molecule Manufacturing
  • 5.4 Contract Development and Manufacturing Organization (CDMO) Services
    • 5.4.1 Drug Development Services
    • 5.4.2 Analytical & Quality Testing
    • 5.4.3 Formulation Development

6 Global Biopharma Contract Services Market, By Research Service

  • 6.1 Introduction
  • 6.2 Oncology
  • 6.3 Inflammation & Immunology
  • 6.4 Vaccines
  • 6.5 Cardiology
  • 6.6 Other Research Services

7 Global Biopharma Contract Services Market, By Technology

  • 7.1 Introduction
  • 7.2 Biologics
  • 7.3 Gene Therapy
  • 7.4 Small Molecules
  • 7.5 Cell Therapy

8 Global Biopharma Contract Services Market, By Application

  • 8.1 Introduction
  • 8.2 Clinical Trials
  • 8.3 Drug Development
  • 8.4 Drug Discovery
  • 8.5 Other Applications

9 Global Biopharma Contract Services Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical Companies
  • 9.3 Biotechnology Companies
  • 9.4 Research Institutes & Academic Centers

10 Global Biopharma Contract Services Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Thermo Fisher Scientific Inc.
  • 12.2 KBI Biopharma
  • 12.3 Lonza Group AG
  • 12.4 Cambrex Corporation
  • 12.5 WuXi AppTec
  • 12.6 Charles River Laboratories
  • 12.7 WuXi Biologics
  • 12.8 AbbVie Contract Manufacturing
  • 12.9 Catalent Inc.
  • 12.10 FUJIFILM Diosynth Biotechnologies
  • 12.11 Samsung Biologics
  • 12.12 Boehringer Ingelheim BioXcellence
  • 12.13 Recipharm AB
  • 12.14 Rentschler Biopharma SE
  • 12.15 AGC Biologics

List of Tables

  • Table 1 Global Biopharma Contract Services Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Biopharma Contract Services Market Outlook, By Service Type (2024-2032) ($MN)
  • Table 3 Global Biopharma Contract Services Market Outlook, By Contract Research Organization (CRO) Services (2024-2032) ($MN)
  • Table 4 Global Biopharma Contract Services Market Outlook, By Preclinical Services (2024-2032) ($MN)
  • Table 5 Global Biopharma Contract Services Market Outlook, By Regulatory Affairs Services (2024-2032) ($MN)
  • Table 6 Global Biopharma Contract Services Market Outlook, By Clinical Trial Services (2024-2032) ($MN)
  • Table 7 Global Biopharma Contract Services Market Outlook, By Contract Manufacturing Organization (CMO) Services (2024-2032) ($MN)
  • Table 8 Global Biopharma Contract Services Market Outlook, By Biologic Manufacturing (2024-2032) ($MN)
  • Table 9 Global Biopharma Contract Services Market Outlook, By Cell and Gene Therapy Manufacturing (2024-2032) ($MN)
  • Table 10 Global Biopharma Contract Services Market Outlook, By Small Molecule Manufacturing (2024-2032) ($MN)
  • Table 11 Global Biopharma Contract Services Market Outlook, By Contract Development and Manufacturing Organization (CDMO) Services (2024-2032) ($MN)
  • Table 12 Global Biopharma Contract Services Market Outlook, By Drug Development Services (2024-2032) ($MN)
  • Table 13 Global Biopharma Contract Services Market Outlook, By Analytical & Quality Testing (2024-2032) ($MN)
  • Table 14 Global Biopharma Contract Services Market Outlook, By Formulation Development (2024-2032) ($MN)
  • Table 15 Global Biopharma Contract Services Market Outlook, By Research Service (2024-2032) ($MN)
  • Table 16 Global Biopharma Contract Services Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 17 Global Biopharma Contract Services Market Outlook, By Inflammation & Immunology (2024-2032) ($MN)
  • Table 18 Global Biopharma Contract Services Market Outlook, By Vaccines (2024-2032) ($MN)
  • Table 19 Global Biopharma Contract Services Market Outlook, By Cardiology (2024-2032) ($MN)
  • Table 20 Global Biopharma Contract Services Market Outlook, By Other Research Services (2024-2032) ($MN)
  • Table 21 Global Biopharma Contract Services Market Outlook, By Technology (2024-2032) ($MN)
  • Table 22 Global Biopharma Contract Services Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 23 Global Biopharma Contract Services Market Outlook, By Gene Therapy (2024-2032) ($MN)
  • Table 24 Global Biopharma Contract Services Market Outlook, By Small Molecules (2024-2032) ($MN)
  • Table 25 Global Biopharma Contract Services Market Outlook, By Cell Therapy (2024-2032) ($MN)
  • Table 26 Global Biopharma Contract Services Market Outlook, By Application (2024-2032) ($MN)
  • Table 27 Global Biopharma Contract Services Market Outlook, By Clinical Trials (2024-2032) ($MN)
  • Table 28 Global Biopharma Contract Services Market Outlook, By Drug Development (2024-2032) ($MN)
  • Table 29 Global Biopharma Contract Services Market Outlook, By Drug Discovery (2024-2032) ($MN)
  • Table 30 Global Biopharma Contract Services Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 31 Global Biopharma Contract Services Market Outlook, By End User (2024-2032) ($MN)
  • Table 32 Global Biopharma Contract Services Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 33 Global Biopharma Contract Services Market Outlook, By Biotechnology Companies (2024-2032) ($MN)
  • Table 34 Global Biopharma Contract Services Market Outlook, By Research Institutes & Academic Centers (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.